HC Wainwright Reiterates “Buy” Rating for Korro Bio (NASDAQ:KRRO)

Korro Bio (NASDAQ:KRRO)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 172.26% from the stock’s current price.

A number of other equities research analysts also recently commented on the company. William Blair assumed coverage on Korro Bio in a research report on Wednesday, August 14th. They issued an “outperform” rating and a $180.00 price objective for the company. Royal Bank of Canada dropped their price objective on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $135.00.

Korro Bio Trading Down 1.4 %

Shares of Korro Bio stock opened at $36.73 on Tuesday. The company’s 50-day simple moving average is $43.88 and its 200-day simple moving average is $51.40. Korro Bio has a 52-week low of $9.15 and a 52-week high of $97.91.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). Equities analysts expect that Korro Bio will post -10.29 EPS for the current year.

Institutional Trading of Korro Bio

A number of institutional investors and hedge funds have recently modified their holdings of the business. Atlas Venture Life Science Advisors LLC bought a new stake in Korro Bio in the fourth quarter valued at $53,648,000. Monashee Investment Management LLC purchased a new position in Korro Bio in the 4th quarter worth about $4,352,000. 72 Investment Holdings LLC acquired a new stake in shares of Korro Bio during the fourth quarter valued at approximately $13,269,000. Eventide Asset Management LLC acquired a new stake in Korro Bio during the 4th quarter valued at $26,185,000. Finally, Bank of New York Mellon Corp purchased a new stake in Korro Bio in the 2nd quarter worth about $649,000. 13.18% of the stock is owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).